---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-064037"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2026-06-02T17:16:53+00:00"
generated_at: "2026-06-02T17:18:45.962985+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP

## Summary
- $30M purchase price for VXM01 IP; payment deferred until first milestone payment under existing license (Phase 2 completion).
- Milestone trigger: completion of Phase 2 study of VXM01 in glioblastoma or pancreatic cancer.
- Buyer may make voluntary partial payments before milestone; full balance due on milestone date.
- Related-party transaction with subsidiary Vaximm; agreement aimed at Swiss transfer pricing simplification.
- Closing occurs upon full payment; no effect on asset transfer if payment default, subject to good faith resolution.

## SEC filing metadata
- accession: 0001213900-26-064037
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2026-06-02T17:16:53+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/ea0293037-8k_osrhold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-064037
- JSON: https://secwatch.observer/filing/0001213900-26-064037.json
- Plain text: https://secwatch.observer/filing/0001213900-26-064037.txt

## Source-grounded claims
- claim_id: d5d6f03da625374539f325ce581137e14724cf4a
  claim: OSR Holdings, Inc. entered into Asset Purchase Agreement with Vaximm AG valued at $30,000,000 (effective 2026-05-27).
  evidence_excerpt: On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000121390026064037/0001213900-26-064037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.